Submit Written Comments
About
Submission windows are open prior to all Board and Stakeholder Council meetings to ensure your feedback is reviewed before any final actions are taken.
CURRENT COMMENT REQUESTS
- NOTICE OF PROPOSED ACTION (9/4/2026):
- The Maryland Prescription Drug Affordability Board proposes to:
- Amend Regulation .05 under COMAR 14.01.01 General Provisions and
To repeal existing Regulation .01 and adopt new Regulation .01, amend Regulations .02—.05, and adopt new Regulation .06 under COMAR 14.01.04 Cost Review Study Process.
The text of the proposed regulations can be found in the September 4, 2026 version of the Maryland Register. Please visit the regulations page for more information on comment submissions. Comments are due October 5, 2026
- The Maryland Prescription Drug Affordability Board proposes to:
ARCHIVE COMMENT REQUESTS
Written Comment Request: Posted 8/31/2026- Comments were due on 9/15/2026.
In accordance with COMAR 14.01.01.05B(4), the Prescription Drug Affordability Board requests public written comment for the cost review study process on:
Dupixent (dupilumab)
Drug Brand Name: Dupixent
Active Moiety or Active Ingredient: dupilumab
Application Number: BLA761055
NDC 11s in the Cost Review Study Process - PDF - 86.75 KB
Written Comment Packet - PDF - 4.91 MB of Comments Received.
AND
Skyrizi (risankizumab)
Drug Brand Name: Skyrizi
Active Moiety or Active Ingredient: risankizumab
Application Number: BLA761105
NDC 11s in the Cost Review Study Process - PDF - 87.53 KB
Written Comment Packet - PDF - 3.51 MBof Comments Received.
Patient experience and clinician input regarding these drugs are of particular interest but all comments concerning these drug products are encouraged. Written comments were due by the close of business, Tuesday, September 15, 2026.